Alder BioPharmaceuticals (ALDR) Trended Somewhat Favorable Press Coverage, Study Finds

Galtero Lara
May 17, 2018

A number of equities analysts recently weighed in on ALDR shares. BidaskClub downgraded Alder BioPharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, March 20th.

Shares of NASDAQ:ALDR traded down $0.13 on Wednesday, hitting $15.02. The company's stock had a trading volume of 1,163,739 shares, compared to its average volume of 1,507,328. Cowen set a $23.00 target price on shares of Alder BioPharmaceuticals and gave the stock a "buy" rating in a research note on Monday, February 26th. The stock now has a consensus rating of "Buy" and an average target price of $27.00. Its up 2.66% from 11.01 million shares, reported previously. Zero analysts have made estimates for Alder BioPharmaceuticals' earnings, with the highest EPS estimate coming in at ($1.07) and the lowest estimate coming in at ($1.37). The titles are as follows: "Alder BioPharmaceuticals® Appoints Jeremy Green to its Board of Directors" announced on April 26, 2018, "Omega's 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More...)" on May 15, 2018, "Alder BioPharma (ALDR) Presents 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term ..." with a publish date: April 24, 2018, "Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results" and the last "Alder BioPharma (ALDR) Has Positive Read-Through from Eli Lilly's Cluster Headache Data - RBC" with publication date: May 15, 2018. PA increased its holdings in shares of Alder BioPharmaceuticals by 9.6% during the 4th quarter. BMO Capital Markets increased their price objective on shares of Alder BioPharmaceuticals to $26.00 and gave the stock an "outperform" rating in a research note on Tuesday, January 9th. The firm has a market cap of $1.03 billion, a PE ratio of -3.04 and a beta of 2.52. Alder Biopharmaceuticals had 8 analyst reports since January 2, 2018 according to SRatingsIntel. On Thursday, February 8 Canaccord Genuity maintained the shares of ALDR in report with "Buy" rating.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Redmile Group LLC boosted its stake in Alder BioPharmaceuticals by 0.4% in the fourth quarter. Redmile Group LLC now owns 6,505,766 shares of the biopharmaceutical company's stock worth $74,491,000 after purchasing an additional 29,000 shares during the period.

More news: Black Ops 4 Cover Art LEAKED via a Website Advert

Alder BioPharmaceuticals stock opened at $13.25 on Friday.

More notable recent Alder Biopharmaceuticals, Inc. Emerald Advisers Inc. PA now owns 1,730,028 shares of the biopharmaceutical company's stock worth $19,809,000 after acquiring an additional 151,551 shares during the period. Palo Alto Investors LP increased its holdings in shares of Alder BioPharmaceuticals by 0.5% during the 1st quarter. AXA now owns 1,087,209 shares of the biopharmaceutical company's stock worth $12,448,000 after acquiring an additional 95,126 shares during the period. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Change of 2.66% for Alder Biopharmaceuticals Inc (NASDAQ:ALDR)'s short interest was noted.

Otros informes por

Discuta este artículo

SIGUE NUESTRO PERIÓDICO